Enthusiasts say high-temperature sessions sharpen focus, improve health, and offer a chance to build contacts. It’s a far cry ...

Pulling the trigger on 555,937 shares, the value of the holding comes in at $6,421,000.Turning to the analyst community, Needham’s Chad Messer tells clients that he has high hopes ahead of the ...

Shares of the U.S.-listed Chinese immuno-oncology company I-Mab (NASDAQ: IMAB) offer strong upside potential, according to a Needham analyst. The I-Mab Analyst: Chad Messer initiated coverage of I ...

Lake Street analyst Chad Messer initiated coverage of Immunome (IMNM) with a Buy rating and $23 price target The company’s lead clinical program, varegacestat for desmoid tumors, is not an ...

With the positive results, Sarepta Therapeutics will seek approval from the Food and Drug Administration later this year for a drug, to treat the Duchenne muscular dystrophy.

In line with Messer’s bullish stance, Nurix is a Strong Buy based on 5 unanimous Buys. The average Nurix price target of $48.80 implies upside potential of 114.9% from the current levels.

“Sweat equity takes on a whole new meaning when you’re networking in a hot room,” says Chad Messer, a managing director at US ...

Shares of the U.S.-listed Chinese immuno-oncology company I-Mab IMAB offer strong upside potential, according to a Needham analyst. The I-Mab Analyst: Chad Messer initiated coverage of I-Mab ...